Chronic GVHD (cGVHD) remains a matter of concern after allo-SCT. Moreover, the incidence of cGVHD is likely to increase as a result of the increasing use of allo-SCT (especially with reduced-intensity conditioning regimens), peripheral blood stem cells as stem cell source and frequent donor lymphocyte infusions, all of which are known to increase the risk of cGVHD. Standard primary treatment of cGVHD remains a combination of corticosteroids (CS) and calcineurin inhibitors. There is no standard therapy for those who fail to respond to CS, and CS-resistant GVHD is associated with high morbidity. 1 In addition, elderly patients are more exposed to the side effects of long-term CS. 2 Thus, therapeutic options are usually limited for those patients. Rituximab (RTX) has been reported recently to be effective in cGVHD. [3] [4] [5] [6] [7] [8] [9] The aim of this letter was to analyze the outcome of 15 patients treated with RTX as salvage therapy for refractory cGVHD in a single center.
This retrospective report describes 15 consecutive patients experiencing severe or refractory cGVHD, and who received intravenous infusions of RTX (375 mg/m 2 per infusion) at weekly intervals for 4 weeks. Responding patients were allowed to receive one or two courses of maintenance therapy according to the attending physician's decision. Response to RTX was assessed 1 month after the last infusion. CR was defined as resolution of all manifestations in involved organs, while PR was defined as an improvement in each involved organ without any new organ involvement, or progression in a previously involved organ. Resistance was defined as lack of a CR/PR 1 month after the last RTX infusion, requirement for alternative therapy or death from GVHD before the last RTX infusion. The benefit in cGVHD was also evaluated in term of CS taper. The CS dose received was assessed 1 month after the last administration of RTX, and compared with the previous CS dose received at the time of first infusion of RTX. Failure was defined as the absence of CR or PR.
Patients' characteristics, GVHD features and outcome are summarized in Table 1 . RTX was administered at a median time of 178 (range, 69-1136) days after allo-SCT, and patients received a median of 5 (range, 1-12) infusions. Except for two patients (nos. 8 and 12) who received RTX as a second-line therapy, all patients had received and failed at least two lines of immunosuppressive therapy. With a median follow-up of 118 days (range, 21-834) from first infusion of RTX, no major toxicities directly related to RTX, according to investigator's assessment, were observed. However, two patients received less than four infusions (three infusions, n ¼ 1; one infusion, n ¼ 1), because of early death from GVHD (no. 9) and patient non-compliance (no. 10). Overall, 10 patients responded to RTX administration (66%; 95% CI, 42-90%) with three CRs. In those responding patients, the patient felt improvement as early as 1 week after the first RTX infusion, with optimal response achieved after the fourth RTX infusion. In addition, RTX allowed a significant reduction of CS dosage (range, 0-83%). Four patients did not respond and died from refractory GVHD, while one responding patient died of disease progression (no. 5). With a median follow-up of 461 days from onset of cGVHD (range, 91-1192), the actuarial survival rate from the first RTX infusion was 60% at 1 year.
Currently, there is no standard 'second-line' therapy for CS-resistant cGVHD. Several candidate drugs were already tested with variable results. 11 At present, there is an urgent need for systematic research to test not only the efficacy of different approaches but also for implementing and developing better standardized, quantifiable and validated measures of therapeutic response in cGVHD. In our study, the global response rate to RTX was high if considered in terms of salvage therapy and/or CS dose reduction. On the other hand, toxicity was negligible. With this background, [3] [4] [5] [6] [7] [8] [9] Despite its limited size, our report demonstrates evidence of beneficial activity mainly in the classical cutaneous, mucosal and liver cGVHD in accordance with findings from other studies. Patients with involvement of other sites are not likely to benefit much from RTX (Figure 1) .
Results achieved with RTX pave the way for further developments with the need for sufficiently powered, well-controlled multi-center prospective trials. In addition, well-designed trials aiming to investigate the addition of immunomodulatory agents to upfront therapy of cGVHD in an effort to improve outcomes and ameliorate CS-related side effects are also needed. As such, the addition of RTX to prednisone for the initial treatment of cGVHD is worth further investigation, both to increase the overall response rate and to enable a more rapid CS taper while incurring less long-term toxicity. 
